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Introduction
Calcific aortic stenosis is a common disorder in the western 
world and is related to aging [1-3]. It is becoming increasingly 
more common with a prevalence of 3% in those aged 75 years 
and over [4]. Aortic valve stenosis causes a left ventricular 
pressure overload and a compensatory myocardial response 
of wall thickening and concentric hypertrophy resulting from 
myocardial muscle fibre thickening and sarcomerogenesis [5]. 
Sarcomeres thicken in response to continued systolic stress 
by adding filaments in parallel but do not increase in length [6]. 
The increase in left ventricular mass in isolated aortic stenosis is 
predictive of heart failure due to systolic dysfunction regardless 
of the severity of the valvular obstruction [7].  In other words the 
compensatory response of ventricular hypertrophy may in itself 
lead to progression of the pathology [7]. 
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Abstract
Background:
Patients at a high operative risk for conventional aortic valve replacement (AVR) may be offered sutureless valve implantation. 
Sutureless valves resemble conventional valves but incorporate an anchoring mechanism without using annular sutures.
Methods
Pre-operative and six month post-operative echocardiography data from our first year, single centre experience of sutureless valves 
was compared to conventional aortic valve replacements in patients matched for operative risk. Left ventricular ejection fraction, 
mean and peak AV gradients and inter-ventricular septal thickness, effective orifice area (EOA) and indexed effective orifice area 
(iEOA) were measured.
Results 
The drops in mean and peak pre- to post-operative gradients were greater in the sutureless group, p=0.039 and p=0.001 respectively. 
Post-operative EOA was 1.69 cm2 and 1.26 cm2 (p=0.001) in the sutureless and conventional groups. Similarly iEOA was 0.93 cm2 and 
0.74 cm2 (p=0.001) in the sutureless and conventional groups. There was also a reduction in patient prosthesis mismatch (PPM) in the 
sutureless group as compared to the conventional group (Chi square test p=0.026). Post-operative inter-ventricular septal thickness 
was 1.13 cm2 in the sutureless group and 1.35 cm2 in the conventional group (p=0.011).
Conclusions 
Use of sutureless valves with a stent framework resulted in larger EOA and iEOA and a diminution in PPM; and lead to a statistically 
significant faster regression in inter-ventricular septal thickness that is a measure of left ventricular mass. The rate and extent 
of regression in left ventricular hypertrophy after AVR is important since it determines long-term survival including mortality, heart 
failure and decreased admission rates.
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Aortic valve replacement relieves the high aortic valve gradient, 
permits regression of the left ventricular wall hypertrophy and 
returns life expectancy back to normal [8,9]. It also leads to 
better quality of life, better NYHA (New York Heart Association) 
status and decreases hospitalisation rates [10]. Surgery was 
denied in one third of elderly patients with severe, symptomatic 
AS with older age and left ventricular dysfunction being the 
most striking characteristics of those denied surgery [11]. The 
greater morbidities and higher-risk profile of the current patient 
cohort has lead to the development of transcatheter aortic valve 
implantation (TAVI) and rapid deployment valves. 
The aim of this study was to assess the difference in the early 
rate of regression in left ventricular hypertrophy between rapid 
deployment valves and conventional xenograft aortic valves, 
since the rate and extent of regression in left ventricular 
hypertrophy after aortic valve replacement is an important 
determinant of long-term survival [12].
Methodology
Data of our first year twenty-two consecutive Perceval sutureless 
valve implantations performed in a single centre was compared 
with a similar series of twenty-two conventional Mitroflow 
pericardial aortic valve replacements. The two cohorts of 
patients we studied were matched for per-operative risk using 
age and current risk assessment scores including additive and 
logistic Euroscore risk scoring for predicted operative mortality. 
Data collected included mortality and stroke rate, risk score, 
angiographic left venticulography data, patient demographic 
data, as well as crossclamp and bypass times. Patients referred 
for a combined aortic valve replacement and coronary artery 
revascularization were excluded from the study. All patients 
underwent procedures with identical blood cardioplegia and 
cardiopulmonary management protocols, and the roller-pump 
heart lung machines, oxygenators and tubing used were sourced 
from the same manufacturers throughout the study. A telephone 
interview was performed in order to assess changes in patients’ 
New York Heart Association (NYHA) status. 
Echocardiography
Echocardiography examination and measurements were 
performed pre- and post-operatively within 6 months of the 
operation following published guidelines from the American 
Society of Echocardiography and other societies [13] in order to 
assess the initial rate of left ventricular regression. Left ventricular 
ejection fraction, mean and peak AV gradients and inter-ventricular 
septal thickness and effective orifice area (EOA) were measured. 
Indexed effective orifice area (iEOA) was calculated in order to 
characterize the degree of patient prosthesis mismatch (PPM). 
An iEOA ≤ 0.85 cm2/m2 was used to designate the threshold for 
aortic valve PPM, values between 0.65–0.85 cm2/m2 categorized 
moderate PPM and < 0.65 cm2/m2 severe PPM following Pibarot’s 
criteria [14]. 
Statistics 
Independent samples t-test was used to compare parameters 
from the sutureless series and conventional controls, using the 
t-test for parametric data and the Mann-Whitney test for non-
parametric data as determined by the Kolgomarov-Smirnoff 
test in SPSS statistics software (SPSS 23, IBM Inc., Armonk, 
New York, USA). Results were presented as mean and standard 
deviation (SD) to indicate the dispersion of the values in each 
dataset. A binomial logistic regression model used to identify 
statistically significant predictors between valve type and pre-
operative and post-operative variables. The chi-squared test 
was used to analyze 2 × 2 contingency tables comparing the two 
valve groups and the presence or absence of patient- prosthesis 
mismatch (PPM). The criterion of a p-value < 0.05 was required 
for statistical significance.
Informed consent was obtained from each patient in this study. 
The study protocol conforms to the ethical guidelines of the 1975 
Declaration of Helsinki as approved by the local institutional 
review committee.
Results
Pre-operative and operative parameters
These parameters are shown in Table 1. The Mitroflow 
patients were smaller and lighter, most likely due to the fact 
that there were more women in this group compared to the 
Perceval group.  This resulted in a higher mass p = 0.021, 
higher body surface area (BSA) p = 0.045 and higher Body 
Mass Index (BMI) p = 0.027 in the Perceval rapid deployment 
group. There was also an advantageous lower cross-clamp 
(p = 0.001) time but not bypass time (p = 0.054) in the rapid 
deployment group. A binomial logistic regression model, 
Table 1
Parameter
Perceval n=22 Mitroflow n=22
P-value
Mean SD Mean SD
P
re
-o
pe
ra
tiv
e
Height (cm) 155.7 7.4 154.24 8.65 0.472
Weight (kg) 78.8 14.1 69.41 13.083 0.021
BSA (m2) 1.78 0.17 1.68 0.183 0.045
BMI (kg/m2) 32.5 5.7 28.99 4.87 0.027
Age (years) 76.9 4.9 78.29 0.507 0.416
Gender  
(M:F ratio) 1.75 - 0.5 - 0.543§
Parsonnet 
score 21.5 6.5 22.7 6.3 0.287
Additive 
Euroscore 7.14 1.32 7.06 1.47 0.425
Logistic 
Euroscore 7.51 3.07 7.69 3.65 0.434
NYHA class 2.04 0.69 2.28 0.70 0.240
O
p
Cross-clamp 
time (min) 42.7 8.2 59.59 10.387 0.000
Bypass time 
(min) 60.8 14.1 71.24 15.193 0.054
P
os
t-
op
er
at
iv
e
Mortality 
(number) 1 - 0 - 0.328
Stroke 
(number) 0 - 0 - 1.000
Bleeding (ml) 456 134 404 162 0.277
Transfusion 
(units) 1.36 0.77 0.89 1.02 0.119
 NYHA class 1.46 0.50 1.31 0.45 0.251
Length of stay 
(days) 11.2 5.5 10.3 6.7 0.665
Differences in patient parameters between Perceval sutureless 
and Mitroflow control groups using Student‘s t-test or Fisher’s 
exact test§. SD standard deviation, BSA body surface area, 
BMI body mass index, EF ejection fraction, ESV end-systolic 
volume, EDV end-diastolic volume, NYHA New York Heart 
Association functional classification.
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between valve types and predictors showed that cross clamp 
time was an independent statistically significant variable (p = 
0.003). There was no statistical difference between the two 
groups in the improvement in NYHA status after operation. 
There was one death in the Perceval group in an 82-year-old 
male that occurred in the fourth post-op week due to acute 
respiratory distress syndrome (ARDS) and multi organ failure.
Echocardiography
Results of pre-operative and post-operative echocardiographic 
parameters are shown in Table 2. Mean and peak pre- to post-
operative gradients decreased more in the sutureless group, 
p=0.039 and p=0.001 respectively. Post-operative EOA was 1.69 
cm2 and 1.26 cm2 (p=0.001) in the sutureless and conventional 
groups. Similarly iEOA was 0.93 cm2 and 0.74 cm2 (p=0.001) in 
the sutureless and conventional groups. Post-operative inter-
ventricular septal thickness was 1.13 cm2 in the sutureless and 
1.35 cm2 in the conventional groups (p=0.011). There was also a 
reduction in patient-prosthesis mismatch (PPM) in the sutureless 
group as compared to the conventional group (p<0.001) using 
Pibarot’s criteria [14]. In the rapid deployment group, there 
were 82% with no mismatch and 9% each with moderate 
and severe mismatch. In the conventional group 54% had no 
mismatch, 32% had mild mismatch and 14% severe mismatch. 
The presence or absence of RDW between the two patient 
groups was statistically significant, Chi-square test p=0.026. 
Discussion
An ideal prosthetic aortic valve should be quick to insert and 
present the lowest possible gradient. The first attribute should 
make aortic valve replacement (AVR) surgery safer, improving 
short-term results and permitting marginal, high-risk patients to 
be operated. The second attribute leads to a lower resistance 
to flow and enhances left ventricular regression and therefore 
improves long-term results.
Category of valves used
The Livanova Perceval S bioprosthetic valve is a surgical 
sutureless self-expanding valve without a sewing ring. It has a 
basic construction similar to the Pericarbon Freedom Stentless 
valve, which however requires suturing of the inflow and outflow 
sides. Instead the Perceval valve has an additional supra-annular 
aortic stent made of a super-elastic alloy. Three temporary and 
removable anchoring sutures allow accurate positioning of the 
prosthesis [15] to the nadir of the sinuses of Valsalva in the aortic 
root. A further important adjunct to the Perceval valve is the sub-
annular curtain, which acts to diminish the risk of paravalvular 
leak as this is an important haemodynamic complication. In a 
population of patients implanted with TAVI valves, paravalvular 
leak was associated with a significant difference in mortality (25 
versus 0%; p = 0.04) [16].  Its major advantage is in shortening 
cross clamp time [17].
The Sorin Mitroflow valve was introduced in 1982 and is an 
established valve with good clinical results [18,19]. In this 
pericardial valve, the leaflet hinge point is located on the outside 
of the strut. This is important as it leads to a larger orifice area 
while at the same time diminishes stresses at the hinge point as it 
is supported by the strut during valve closure when the pressure 
gradient across the valve is the highest. 
Shrestha reported a cumulative life expectancy survival with 
Perceval valves that was worse than conventional biological 
valves from 2.5 years post-operatively. However in this study the 
sutureless group had a statistically significant higher operative 
risk with a logistic EuroSCORE of 20.4 ± 10.7 as compared to 
the conventional group at 16.7 ± 10.4 (p = 0.05) [20]. Therefore 
patient groups in this study were matched for operative risk order 
to eliminate this confounding factor.
Echocardiography
Echocardiography showed a doubling in post-operative in iEOA 
with Perceval sutureless valves, compared to a 33% increase 
in the Mitroflow conventional group. The difference in post-
operative effective orifice area was probably due to the absence 
of a sewing ring in the Perceval valve and also because the stent 
exerts a radial distending force that may stretch the annulus. 
Though both the peak and mean gradients were lower, this did not 
reach statistical significance. However the differences in mean 
and peak pre- to post-operative gradients were greater in the 
sutureless group, p=0.039 and p=0.001 respectively. Our results 
contrast with those reported by Sepehripour that indicated that 
sutureless valves suffer from a higher mean valve gradient than 
conventional AVs [21]; however, this paper compared sutureless 
valves from six papers to the conventional arm of the PARTNER 
Trial (transcatheter versus surgical aortic-valve replacement in 
high-risk patients). 
The post-operative EOA was 0.43cm2 lower and the iEOA 0.19cm2 
lower in the Perceval sutureless group compared to the Mitroflow 
Table 2
Echocardiographic 
parameters
Perceval Mitroflow
valve SD valve SD P-value
Pre-op EF(%) 56.83 12.1 60.11 8.2 0.352
Post-op EF (%) 59.49 4.2 59.06 10.3 0.866
Pre-op IV septum (cm) 1.54 0.31 1.61 0.38 0.585
Post-op IV septum (cm) 1.13 0.24 1.35 0.27 0.011
Pre-op mean gradient 
(mmHg) 60.25 15.0 54.18 15.9 0.258
Post-op mean gradient 
(mmHg) 13.41 5.4 18.53 12.4 0.108
Pre- to post-op mean 
gradient drop (mmHg) 46.84 16.3 35.6 19.8 0.039
Pre-op peak gradient 
(mmHg) 97.69 21.6 72.97 24.7 0.003
Post-op peak gradient 
(mmHg) 23.17 9.8 26.56 7.8 0.131
Pre- to post-op peak 
gradient drop (mmHg) 74.51 23.8 46.41 24.4 0.001
Pre-op EOA (cm2) 0.80 0.20 0.89 0.32 0.308
Post-op EOA (cm2) 1.69 0.44 1.26 0.24 0.001
Change from pre-op to 
postop EOA 0.89 0.45 0.37 0.45 0.001
Pre-op iEOA (cm2/m2) 0.45 0.12 0.53 0.20 0.124
Post-op iEOA (cm2/m2) 0.93 0.22 0.74 0.11 0.001
Change from pre- to post-
op iEOA 0.48 0.23 0.21 0.25 0.001
Differences in pre-operative and post-operative 
echocardiographic parameters between Perceval sutureless 
and Mitroflow control groups. SD standard deviation, EF ejection 
fraction, IV inter-ventricular, EOA effective orifice area, iEOA 
indexed effective orifice area.
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conventional group. This improvement in indexed effective orifice 
area in the Perceval group resulted in a statistically significant 
reduction in PPM in the Perceval group (p<0.001), even though 
the patients in the Perceval group were heavier (p=0.021). This 
is important since PPM is associated with poorer long-term 
outcome due to worse haemodynamics and less regression 
of ventricular hypertrophy [16]. No aortic root enlargement 
operations are performed routinely in our centre as although 
aortic root enlargement may reduce trans-valvular gradients 
and therefore the incidence of prosthesis- patient mismatch, 
this has not been shown to result in an improvement in long-
term clinical outcomes [22]. The advantageous increase in EOA 
and iEOA in the stentless Perceval group is demonstrated in the 
early regression in left ventricular hypertrophy by a statistically 
significant difference of 0.22cm in post-operative inter-ventricular 
septal thickness between the two groups p=0.011.
Our results compare favourably with those from other series; 
for example mean effective orifice area (EOA) in our series was 
1.69 ± 0.44 cm2 compared to 1.4 ± 0.4 cm2 and 1.6 ± 0.4 cm2 in 
other series. Similarly mean gradient was 13.4 ± 5.4 mmHg whilst 
results in published series ranged from 10 ± 5 to 14 ± 6 mmHg 
and peak gradient was 23.2 ± 9.9 mmHg compared to a range 
from 19 ± 8 to 27 ± 11 mmHg [23].
Advantages of rapid deployment valves
Rapid deployment AVR can be considered as a substitute to 
conventional AVR, especially for elderly patients with intermediate 
to high operative risk [24]. Another use is as a replacement in 
stentless bioprosthesis failure [25]. Rapid deployment valves 
reduce complexity of conventional valve operations [26] yet 
permit precise reproducible positioning [15]. 
Whilst the design of rapid deployment valves is similar in concept to 
Trans Aortic Valve Implantation (TAVI) prosthesis [27], the surgical 
approach differs in that it provides direct visualization and permits 
excision of the aortic valve and adjacent calcifications instead of 
lateral compression by the TAVI stent. The decalcification of the 
valve is important in that it may reduce the possibility of embolic 
showers particularly to the brain although this remains unproven 
[28]. The major degree of crimping required with TAVI valves may 
reduce prosthesis durability [29]. 
The reduction in implantation time with rapid deployment 
valves results in lower cross-clamp times should contribute to a 
reduction in postoperative complications [30,31]. The absence of a 
conventional sewing ring should lead to improved haemodynamics 
with greater EOA and lower post-operative aortic valve gradients, 
particularly important in older patients with small aortic roots 
[20]. Sutureless valves result in a higher rate of heart block 
compared to conventional AVR, with approximately 10% requiring 
a permanent pacemaker [24]. The mortality, neurological deficit, 
renal failure and post-operative bleeding rates of sutureless and 
conventional valves are similar, but there is an increased incidence 
of endocarditis and paravalvular leaks [21]. 
Left ventricular regression
Left ventricular hypertrophy is a dangerous consequence of the 
pressure load on the left ventricle resulting from aortic stenosis 
[32]. There is an independent relationship between indexed-EOA 
and the extent of regression in left ventricular mass after AVR 
[33]. There is lesser regression of left ventricular hypertrophy 
after AVR with PPM, with a smaller decrease in chamber internal 
dimension in patients with PPM compared to those without 
a mismatch [34]. In our series sutureless valve implantation 
resulted in a larger iEOA and a marked decrease in PPM and this 
would be expected to result in more complete LV regression. An 
enhanced LV mass regression after AVR is associated with better 
long-term survival [35]. We have shown that there is a statistically 
significant difference in the rate of early (before 6 months post-op) 
LV regression when a sutureless prosthesis was used, suggestive 
of better long-term outcomes including mortality, heart failure 
and decreased admission rates [10,36].
Limitations
This case-matched study was performed with a small number of 
patients. This may add biases caused by not assigning patients 
randomly to a treatment arm, resulting in an augmented risk of 
introducing confounding variables. 
Conclusion
Use of sutureless valves resulted in larger EOA and iEOA, 
decreased PPM and lead to a statistically significant faster 
regression in early inter-ventricular septal thickness, indicating 
early left ventricular mass reduction and modelling. The rate 
and extent of regression in left ventricular hypertrophy after 
aortic valve replacement is an important determinant of long-
term survival including mortality, heart failure and decreased 
admission rates. 
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